- Home
- EDN vs AMLX Comparison
EDN vs AMLX Comparison
Compare EDN & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$13.88
Company Overview
Basic Information| Metric | EDN | AMLX |
|---|---|---|
| Founded | 1992 | 2014 |
| Country | Argentina | United States |
| Employees | N/A | 123 |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2007 | 2022 |
Fundamental Metrics
Financial Performance| Metric | EDN | AMLX |
|---|---|---|
| Price | $33.01 | $13.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $17.43 |
| AVG Volume (30 Days) | 142.1K | ★ 1.4M |
| Earning Date | 08-11-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $1,678,118,877.00 | N/A |
| Revenue This Year | $32.93 | N/A |
| Revenue Next Year | $24.64 | N/A |
| P/E Ratio | $20.87 | ★ N/A |
| Revenue Growth | ★ 3.69 | N/A |
| 52 Week Low | $14.38 | $2.60 |
| 52 Week High | $51.69 | $16.96 |
Technical Indicators
Market Signals| Indicator | EDN | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 53.21 | 48.95 |
| Support Level | $33.65 | $13.50 |
| Resistance Level | $36.70 | $15.06 |
| Average True Range (ATR) | 2.31 | 0.92 |
| MACD | -0.38 | -0.03 |
| Stochastic Oscillator | 43.18 | 33.00 |
Price Performance
Historical Comparison EDN
AMLX
About EDN Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor)
Empresa Distribuidora y Comercializadora Norte SA is engaged in the distribution and sale of electricity. The firm's concession area covers the northern portion of the city of Buenos Aires mainly to residential, commercial, industrial, and public service.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.